Indian drug giant Ranbaxy trims losses but future is bleaker

February 5, 2014

Ranbaxy Laboratories, India's biggest generic drugmaker by sales, reported a narrower quarterly loss on Wednesday thanks to rising sales in key markets and currency gains.

But Ranbaxy, majority-owned by Japan's Daiichi Sankyo, faces an uphill battle to repeat the performance next quarter after the US Food and Drug Administration slapped another import ban on the company's products.

The FDA announced the ban last month, citing concerns about "good manufacturing practice" at a plant in northern India. The move is expected to put severe pressure on future earnings.

The regulator has already barred products from three other Ranbaxy plants from entering the United States, which accounts for 40 percent of the company's revenues.

Ranbaxy reported a consolidated net loss of 1.59 billion rupees ($25.6 million) for the quarter ended December, compared with a 4.92 billion rupee loss a year earlier.

"Ranbaxy has been strengthening its base business in key markets including India, Eastern Europe & CIS and the USA which has helped us recover our margins," Arun Sawhney, chief executive officer and managing director, said in a statement.

"We are facing some major regulatory challenges and are disappointed with the developments," said Sawhney, adding that the firm will "do whatever" is needed to address FDA concerns.

Shares of Ranbaxy rose 5.69 percent to end at 340.05 rupees on the Bombay Stock Exchange. The stock has lost 22.7 percent of its value in the past 12 months.

Ranbaxy is more than 60 percent owned by Daiichi Sankyo, which bought the firm in 2008 believing its dominance in cheaper generic medicines and developing markets would help the Japanese firm increase sales as Daiichi's drugs came off patent.

But its foray into the high-growth copycat drugs arena has brought the Japanese drugmaker only financial pain as the Indian firm has come under fire over a string of safety problems.

In January the FDA banned the firm's Toansa plant from sending active ingredients to its laboratories in the United States to make drugs.

The move triggered a stock write-off worth 2.6 billion rupees in the December quarter, Ranbaxy said Wednesday.

Net sales for Ranbaxy, headquartered in Gurgaon near New Delhi, rose 7.04 percent to 28.59 billion rupees in the quarter ended December from a year earlier.

Explore further: India's drugmaker Ranbaxy swings into quarterly net loss

Related Stories

India's drugmaker Ranbaxy swings into quarterly net loss

October 29, 2013
India's biggest generic drugmaker Ranbaxy Laboratories swung into a net loss in the third quarter ended September from a profit a year earlier, owing to a weak rupee and foreign exchange losses.

Shares of India's Ranbaxy slide 19% on new US FDA ban

January 24, 2014
Shares in one of India's biggest drugmakers, Ranbaxy Laboratories, slid 19 percent Friday after the US Food and Drug Administration suspended imports from a fourth manufacturing plant of the firm.

Ranbaxy taking 'stringent steps' to end US FDA ban

September 21, 2013
India's biggest drugmaker by sales, Ranbaxy Laboratories, has assured shareholders it is taking "stringent steps" to resolve a US ban on imports of medicines made at its newly renovated showcase plant.

US health watchdog curbs exports from India's Wockhardt

November 27, 2013
The US health regulator has restricted exports from a plant owned by Indian generic drugmaker Wockhardt in the latest ban on its products, sending the company's shares tumbling 14 percent on Wednesday.

US halts drug imports from Ranbaxy plant in India

January 23, 2014
U.S. health regulators said Thursday they are barring imported drugs from an overseas factory operated by Ranbaxy Laboratories, India's largest drugmaker, due to quality control violations.

Indian drugmaker Ranbaxy faces new US regulation woes (Update 2)

September 16, 2013
Shares in Indian generic drugs giant Ranbaxy Laboratories crashed by as much as 35 percent on Monday after the US Food and Drug Administration suspended imports from one of its factories.

Recommended for you

Data revealed under FOI shows benefits of multiple sclerosis drug currently blocked by regulators

August 17, 2017
A drug that is blocked by the EU regulatory system has now been found to improve the quality of life of people with multiple sclerosis (MS), according to a study by Queen Mary University of London (QMUL).

Opioids overused in migraine treatment, regardless of race, study finds

August 17, 2017
African-Americans are more likely to experience debilitating migraine headaches than whites, but a new study probing the issue found no evidence of racial disparities in treatment practices.

Finding better ways to reduce serious drug side effects

August 14, 2017
Many of the medicines we depend on to treat disease—and even to save our lives—pose potentially serious risks along with their benefits. Data from the U.S. Centers for Disease Control and Prevention indicate that about ...

Ultrasound-triggered liposomes for on-demand, local anesthesia

August 10, 2017
Researchers at Boston Children's Hospital have found a new way to non-invasively relieve pain at local sites in the body; such systems could one day improve pain management by replacing addictive opioids and short-lasting ...

Independent pharmacies and online coupons help patients save money on drugs

August 8, 2017
Uninsured patients or those with limited prescription drug coverage can save significant money by buying their drugs at independent pharmacies instead of big box, grocery or chain drug stores and by using discount coupons, ...

New study generates more accurate estimates of state opioid and heroin fatalities

August 7, 2017
Although opioid and heroin deaths have been rising dramatically in the U.S., the magnitude of the epidemic varies from state to state, as does the relative proportion of opioid vs heroin poisonings. Further complicating the ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.